Stelios Bouralexis - Concepedia

Author

Stelios Bouralexis

The University of Adelaide

Also Known As

S Bouralexis, S. Bouralexis, Stelios Bouralexis

Publications

998

Citations

H-Index

Concepts

All Affiliations

The University of Adelaide Royal Adelaide Hospital Hanson Institute The University of Melbourne South Australia Pathology

About

Stelios Bouralexis is an author at The University of Adelaide specializing in medicine, cell biology, and tumor microenvironment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	462
2	Cell Biology	8	8	446
3	Orthopaedics	3	3	170
4	Immunology	2	2	83
5	Cellular Physiology	1	1	19

Stelios Bouralexis

Publications

879

Citations

H-Index

Page 1

	Year	Citations
Expression of Osteoclast Differentiation Signals by Stromal Elements of Giant Cell Tumors Gerald J. Atkins, David R. Haynes, Stephen E. Graves, Journal of Bone and Mineral Research	2000	194
Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2l/trail‐induced apoptosis Andreas Evdokiou, Stelios Bouralexis, Gerald J. Atkins, International Journal of Cancer	2002	128
Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone Gerald J. Atkins, Stelios Bouralexis, David R. Haynes, Bone Giant Cell TumorsSclerostinBone Morphogenic ProteinPathologyBone Metabolism	2001	104
IL-23 Inhibits Osteoclastogenesis Indirectly through Lymphocytes and Is Required for the Maintenance of Bone Mass in Mice J Quinn, Natalie A. Sims, Hasnawati Saleh, The Journal of Immunology	2008	95
Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis Andreas Evdokiou, Agatha Labrinidis, Stelios Bouralexis, Bone Bone DiseaseZoledronic Acid ResemblesBone Morphogenic ProteinBone RepairCell Death	2003	70
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL Lisa M. Butler, Vasilios Liapis, Stelios Bouralexis, International Journal of Cancer Breast OncologyChemoprevention StrategyHistone Deacetylase InhibitorApoptosisCell Death	2006	67
Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis Gerald J. Atkins, Stelios Bouralexis, Andreas Evdokiou, Bone Human OsteoblastsApoptosisBone RepairCell DeathOsteoarthritis	2002	66
Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy Stelios Bouralexis, David M. Findlay, Gerald J. Atkins, British Journal of Cancer Chemoprevention StrategyApoptosisImmunologyCell DeathProgressive Resistance	2003	64
Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro Akira Nakamura, Chi Ly, Mirijana Cipetić, Bone SclerostinDevelopmental BiologyOsteoblast DifferentiationBone Morphogenic ProteinOsteoarthritis	2007	34
Enhanced Apoptosis of Soft Tissue Sarcoma Cells with Chemotherapy: A Potential New Approach Using Trail Mark Clayer, Stelios Bouralexis, Andreas Evdokiou, Journal of orthopaedic surgery Cancer ResearchEnhanced ApoptosisConventional ChemotherapySarcoma Cell CultureMalignant Disease	2001	22

Page 1